Vats

Atom Power Appoints New CEO as Company Enters Next Phase of Growth

Retrieved on: 
Wednesday, April 3, 2024
EV, General Electric, Culture, Growth, Partnership, Danaher Corporation, L.A. Live, IBM, Vats, SK Group, Artificial intelligence, Management

Vats, an accomplished and visionary leader, brings a wealth of experience to Atom Power.

Key Points: 
  • Vats, an accomplished and visionary leader, brings a wealth of experience to Atom Power.
  • With a proven track record of driving growth and innovation in technology and Artificial Intelligence in utilities, energy, and related industries, Vats is poised to lead Atom Power into a new era of success.
  • Vats joins Atom Power as the company ushers in a new phase of growth, spurred on by global demand for infrastructure to support EV adoption and related technologies.
  • His exceptional leadership skills, strategic insights, and deep industry knowledge make him the ideal choice to lead Atom Power.

Gemini Selects TaxBit as its CESOP Reporting Solution

Retrieved on: 
Thursday, January 25, 2024
Partnership, API, Gemini, Vats, XML, Medical device

NEW YORK, Jan. 25, 2024 /PRNewswire/ -- TaxBit, the leading provider of tax and compliance solutions for digital assets, announced today that it has been selected by Gemini, a prominent cryptocurrency exchange, as its CESOP reporting solution. Gemini's decision to integrate with TaxBit expands the two companies' long-standing relationship, underscoring its dedication to regulatory compliance in the dynamic digital asset landscape. The collaboration aims to streamline Gemini's reporting obligations across the EU, ensuring adherence to CESOP guidance and local jurisdiction intricacies. "Tax requirements have evolved rapidly across the globe as the digital asset ecosystem matures. Our integration with TaxBit's CESOP reporting solution allows us to quickly adapt to changes in the tax regulatory environment in the EU so that we can efficiently meet the tax needs of our customers," said Jill Dymtrow, Director of Tax Information Reporting at Gemini.

Key Points: 
  • NEW YORK, Jan. 25, 2024 /PRNewswire/ -- TaxBit, the leading provider of tax and compliance solutions for digital assets, announced today that it has been selected by Gemini, a prominent cryptocurrency exchange, as its CESOP reporting solution.
  • The collaboration aims to streamline Gemini's reporting obligations across the EU, ensuring adherence to CESOP guidance and local jurisdiction intricacies.
  • Our integration with TaxBit's CESOP reporting solution allows us to quickly adapt to changes in the tax regulatory environment in the EU so that we can efficiently meet the tax needs of our customers," said Jill Dymtrow, Director of Tax Information Reporting at Gemini.
  • Key Features of TaxBit's CESOP Reporting Solution:
    Automates complex quarterly reporting obligations.

TaxBit Launches Innovative CESOP Reporting Solution for Digital Assets

Retrieved on: 
Thursday, December 14, 2023
Crypto, XML, Vats, Report, API, VAT, Cryptocurrency, Medical device

NEW YORK, Dec. 14, 2023 /PRNewswire/ -- TaxBit, the leading provider of compliance solutions for digital assets, announced the launch of its CESOP Compliance Platform, catering to crypto exchanges operating in the EU. This revolutionary solution addresses the upcoming CESOP compliance requirements set to commence in Q1 2024, underscoring TaxBit's dedication to upholding tax compliance for digital asset enterprises within the continually evolving regulatory environment.

Key Points: 
  • NEW YORK, Dec. 14, 2023 /PRNewswire/ -- TaxBit, the leading provider of compliance solutions for digital assets, announced the launch of its CESOP Compliance Platform, catering to crypto exchanges operating in the EU.
  • This revolutionary solution addresses the upcoming CESOP compliance requirements set to commence in Q1 2024, underscoring TaxBit's dedication to upholding tax compliance for digital asset enterprises within the continually evolving regulatory environment.
  • The Central Electronic System of Payment information, known as "CESOP," mandates quarterly reporting to European Union member states for cross-border payments, with the first reporting due by April 30, 2024.
  • TaxBit's CESOP Compliance Platform helps enterprises automate complex quarterly reporting obligations across the EU landscape.

With Rising International Popularity, Rinna Beauty Localizes Website Product Offerings and Costs in Markets Worldwide

Retrieved on: 
Wednesday, July 12, 2023
Cosmetics, Online Retail, Retail, Technology, Electronic Commerce, Internet, SEL, Eye, Philosophy, Beauty, Multimedia, Vats, Lip

Driven by her philosophy that “Beauty has no borders,” actress, entrepreneur and beauty expert Lisa Rinna has partnered with New York-based brand incubator SEL Beauty to tailor her increasingly popular Rinna Beauty website to the needs of customers around the world.

Key Points: 
  • Driven by her philosophy that “Beauty has no borders,” actress, entrepreneur and beauty expert Lisa Rinna has partnered with New York-based brand incubator SEL Beauty to tailor her increasingly popular Rinna Beauty website to the needs of customers around the world.
  • View the full release here: https://www.businesswire.com/news/home/20230712785992/en/
    Lisa Rinna, founder of Rinna Beauty, applying the Rinna Beauty Larger Than Life Plumping Gloss.
  • Just as every woman customizes her beauty regimen, Rinna Beauty now offers a customized website for each region that lists products in the local currency with import duty, value-added taxes (VATs) and freight shipping costs automatically included.
  • “I’m excited that Rinna Beauty is now more easily available to anyone nearly anywhere in the world.

Industrial AI Company ONEPREDICT Appoints COO to Expand Global Business and Lead its New US Entity

Retrieved on: 
Thursday, January 19, 2023
PDM, General Electric, Vats, IOT, CGO, AI, Xerox, Research, IBM, Danaher, PARC, Airline

SEOUL, South Korea, Jan. 19, 2023 /PRNewswire/ -- ONEPREDICT, a South Korean industrial AI-based facility predictive maintenance (PdM) solution company, has named Bharat Vats as the Chief Operating Officer (COO) of its newly incorporated US entity (San Jose, CA) and Chief Growth Officer (CGO) of South Korea in efforts to make inroads into the global market.

Key Points: 
  • - ONEPREDICT Incorporated its first overseas entity in San Francisco, US, to expand global customer touchpoints.
  • Prior to joining ONEPREDICT, as Chief Revenue Officer, Vats was leading revenue and business growth of the AI and IoT-based PdM business at PARC, a research and development company owned by Xerox Corporation.
  • ONEPREDICT plans to expand its global business by increasing touchpoints with customers and partners in North America, leveraging the incorporation of the US entity and the recruitment of the local business expert as the cornerstone.
  • As the country's industrial AI leader, ONEPREDICT provides GUARDIONE® product family that offers a predictive and prescriptive solution to key industrial assets through the company's original industrial AI technology.

Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet

Retrieved on: 
Thursday, October 27, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Perception, Gesellschaft mit beschränkter Haftung, Medicine, Overactive bladder, Plasma, Liver, Breast milk, Instagram, Safety, 100 Best Workplaces in Europe, Vitamin, Taste, AES, Headache, AUC, Kopp, Adult, Orange County Business Journal, Drug development, I, Sex, Diarrhea, Digoxin, Neurogenic bladder dysfunction, FDA, Burden, Patient, Food additive, Urination, Food, Kidney, Urinary incontinence, Man, Science, Twitter, OAB, Urinary urgency, Vibegron, Nausea, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Sore throat, Urine, Urinary retention, Prevalence, NYSE, Upper respiratory tract infection, Nasal congestion, Urinary tract infection, Vats, Allergy, Dysphagia, Nocturia, Constipation, Public health, Pharmaceutical industry, Medical imaging, Perfume, Dietary supplement, Sexton, Cmax

In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce.

Key Points: 
  • In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce.
  • All patients received one treatment with intact tablet and one with crushed tablet, mixed with applesauce.
  • Additional reported TEAEs experienced by 2 participants were constipation (crushed, 13.3%; intact 6.7%) and nausea (crushed 6.7%, intact 0%) .
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences® Named 17th on the List of Fortune® Best Workplaces in BioPharma™ (2022)

Retrieved on: 
Wednesday, September 7, 2022
Clinical Trials, Human Resources, Biotechnology, Seniors, Other Science, Health, Research, Professional Services, Consumer, Publishing, Science, Nursing, Communications, Medical Supplies, Other Health, FDA, Practice Management, Physical Therapy, Managed Care, Pharmaceutical, Business, Medical Devices, Infectious Diseases, Hospitals, Fitness & Nutrition, People, Work, CEO, Man, Culture, Kopp, I, Upper respiratory tract infection, Organization, Urinary retention, Urinary urgency, Medicine, Urine, Overactive bladder, Twitter, Orange County Business Journal, Adult, Gesellschaft mit beschränkter Haftung, Nausea, Patient, Health, Sex, Great Places, Kidney, The Last Best Place, Vitamin, Headache, FDA, Nasal congestion, Diarrhea, Public health, Liver, LinkedIn, Multimedia, Instagram, Breast milk, 100 Best Workplaces in Europe, Sore throat, NYSE, Urinary tract infection, Vats, Achievement, Urinary incontinence, Urination, Allergy, Digoxin, Neurogenic bladder dysfunction, Nocturia, Burden, Feedback, Place, OAB, Health insurance, Management, Pharmaceutical industry, Risk management, Dietary supplement, Biopharma LLC, Sexton, Fortune, VideoRay UROVs

Great Place to Work and Fortune magazine have named Urovant Sciences as one of the 2022 Best Workplaces in BioPharma .

Key Points: 
  • Great Place to Work and Fortune magazine have named Urovant Sciences as one of the 2022 Best Workplaces in BioPharma .
  • Its an honor to be recognized by Fortune and Great Place to Work, said James Robinson, CEO of Urovant Sciences.
  • The Fortune Best Workplaces in BioPharma list is highly competitive.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo and Powered by People and Possibilities are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting

Retrieved on: 
Friday, May 13, 2022
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, American Urological Association, Urination, Sex, Medicine, Urinary urgency, Urine, Sore throat, Overactive bladder, Vitamin, Neurogenic bladder dysfunction, Female, Nasal congestion, Urinary incontinence, Headache, Twitter, Science, Oakland University, Burden, Allergy, Nausea, Professor, Journal, Liver, Breast milk, Woman, Medical school, Beaumont, Vats, The Journal of Urology, Man, Urinary tract infection, Trial of the century, Diarrhea, NYSE, Department, Urinary retention, Catheter, Kopp, Digoxin, Doctor of Philosophy, I, Micturition syncope, Beaumont Hospital, Patient, OAB, Adult, FDA, Public health, LinkedIn, MD, Kidney, Upper respiratory tract infection, Population, Injection, Nocturia, Cystoscopy, Gesellschaft mit beschränkter Haftung, Safety, Pharmaceutical industry, Dietary supplement, Urology, Sexton

This was a prespecified, 12-week interim analysis of a 48-week multicenter, randomized, double-blind, placebo-controlled, dose-escalation study ( NCT04211831 ).

Key Points: 
  • This was a prespecified, 12-week interim analysis of a 48-week multicenter, randomized, double-blind, placebo-controlled, dose-escalation study ( NCT04211831 ).
  • Treatment-emergent adverse events occurred in 45.5% of patients receiving URO-902 24 mg, 46.2% receiving 48 mg, and 50.0% receiving placebo.
  • We are encouraged by these promising interim safety and efficacy findings for URO-902, said Sef Kurstjens, MD, PhD, Executive Vice President and Chief Medical Officer of Urovant Sciences.
  • UROVANT, UROVANT SCIENCES, the UROVANT SCIENCES logo, GEMTESA, and the GEMTESA logo are trademarks of Urovant Sciences GmbH, registered in the U.S. and in other countries.

Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 American Urological Association Annual Meeting

Retrieved on: 
Wednesday, April 13, 2022
Health, Genetics, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Patient, Vitamin, Breast milk, Overactive bladder, Kidney, Urinary urgency, Urination, Medicine, Public health, Woman, Cystoscopy, I, Urinary tract infection, Twitter, Adult, Nasal congestion, Incidence, Neurogenic bladder dysfunction, Urinary retention, Sore throat, Burden, Digoxin, Kopp, LinkedIn, Injection, Vats, Urine, Nocturia, Allergy, Sex, Female, Liver, Urinary incontinence, Man, Headache, NYSE, Safety, FDA, OAB, Diarrhea, Nausea, Upper respiratory tract infection, Pharmaceutical industry, Medical imaging, Dietary supplement, Urology, Sexton

URO-902 has the potential to be the first gene therapy for patients with OAB.

Key Points: 
  • URO-902 has the potential to be the first gene therapy for patients with OAB.
  • If approved, this innovative treatment has the potential to address an unmet need for patients who have failed oral pharmacologic therapies.
  • Secondary endpoints were changes from EMPOWUR baseline at week 52 in average daily micturitions, UUI, urgency, and total urinary incontinence.
  • Sumitovant is a global biopharmaceutical company leveraging data-driven insights to rapidly accelerate development of new potential therapies for unmet patient conditions.

SentinelOne Promotes Nicholas Warner to President, Vats Srivatsan Joins as COO

Retrieved on: 
Thursday, April 7, 2022
Software, Technology, Internet, Security, Cloud, Company, CXO, Trust, Organization, COO, Motorola Mobility, McKinsey & Company, Partner, Vats, Growth, F100, NYSE, Palo Alto Networks, Security, CEO, Industry, Google Cloud, Business operations, IOT, Warner, IPO, Corporation, Management, SentinelOne

SentinelOne (NYSE: S), an autonomous cybersecurity platform company, today announced that Chief Operating Officer Nicholas Warner has been promoted to President, Security and Vats Srivatsan has been appointed Chief Operating Officer.

Key Points: 
  • SentinelOne (NYSE: S), an autonomous cybersecurity platform company, today announced that Chief Operating Officer Nicholas Warner has been promoted to President, Security and Vats Srivatsan has been appointed Chief Operating Officer.
  • Im pleased to welcome Vats Srivatsan as COO, leading our global expansion, growth, and operational alignment as we scale to the next level.
  • Warner joined SentinelOne as Chief Revenue Officer in 2017 and was promoted to Chief Operating Officer in 2019.
  • Vats brings more than 30 years of professional experience to SentinelOne, including a deep understanding of cloud and growth transformations.